NTRA News and Press, Natera Inc.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that its latest research and data on prenatal and reproductive genetics will be presented at the 28th International Conference on Prenatal Diagnosis and Therapy. Hosted by the Internationa...

2024-06-27 10:17:45 ET Information Technology has been the best performing name among all 11 S&P 500 ( SP500 ) sectors in the first half of 2024, but Cathie Wood’s actively managed ARK Innovation ETF ( NYSEARCA: ARKK ) - which aims to provide investors exposure to dis...

First-of-its-kind study in gastroesophageal adenocarcinoma using Signatera to guide treatment and assess the efficacy of a novel HER2-directed adjuvant treatment Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new gastroes...

2024-06-23 13:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Donor Quantity Score (DQS) technique is unique to Natera, improving detection of both acute cellular rejection and antibody-mediated rejection Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart!...

2024-06-06 07:00:00 ET Summary GeneDx Holdings Corp. focuses on delivering precise medical diagnostic outcomes through its genomic expertise and rare disease dataset. Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) are key revenue drivers, growing 96% in the first q...

2024-06-03 11:04:50 ET Summary Today, we look at Natera, Inc., a diagnostic and molecular testing services company that has seen its stock rise over 150% since late October. The company achieved cash flow break even status in the first quarter ahead of schedule as Natura delivered...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 7:40 a.m. PT (10:40 a.m. ET). A live webcast may be accessed through the investor...

2024-06-03 06:00:09 ET Tycho Peterson from Jefferies issued a price target of $142.00 for NTRA on 2024-06-03 04:57:00. The adjusted price target was set to $142.00. At the time of the announcement, NTRA was trading at $106.53. The overall price target consensus is at $10...

2024-06-02 23:01:06 ET Summary Duquesne Family Office's 13F portfolio value increased from $3.35B to $4.39B in Q1 2024. The largest five stakes in the portfolio are Microsoft, Coupang, Teck Resources, Vistra Corp., and Natera, Inc. Stanley Druckenmiller's family office made ne...